FreeTheAI

Opus Genetics Reports Positive Data for Two Lead Gene Therapy Programs

MixedMedium impact
IRD$4.05 −1.22%

Opus Genetics, Inc. (IRD) released updated clinical data for two of its inherited retinal disease treatment candidates. In a Phase 1/2 trial evaluating OPGx-BEST1, three out of four evaluable patients experienced improvements in retinal sensitivity. Separately, a Phase 1/2/3 study of OPGx-LCA5 demonstrated sustained improvements in adult patients lasting up to 24 months, alongside pediatric visual gains observed through six months.

The findings offer early clinical evidence for both gene therapy candidates. The initial sensitivity improvements seen in the lower-dose OPGx-BEST1 group help validate the therapeutic approach as higher-dose testing progresses. Meanwhile, the multi-year durability established in adult OPGx-LCA5 participants strengthens the foundation for potential regulatory advancement and commercial development. Shares of Opus Genetics closed down 2.07% at $4.015 following the announcement.

Investors will be watching for further updates from the OPGx-BEST1 high-dose cohort, which has completed enrollment with 11 patients. For OPGx-LCA5, the primary focus shifts to pivotal development, with Phase 3 patient dosing scheduled to begin in the fourth quarter of 2026.

Key points

  • Opus Genetics observed retinal sensitivity improvements in three of four evaluable patients in its Phase 1/2 OPGx-BEST1 trial.
  • Adult patients in the Phase 1/2/3 OPGx-LCA5 study maintained vision improvements for up to 24 months, while pediatric gains reached six months.
  • Enrollment for the higher-dose Cohort 2 of the OPGx-BEST1 trial has completed with 11 patients.
  • Phase 3 dosing for the OPGx-LCA5 gene therapy program is expected to begin in the fourth quarter of 2026.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the results of Opus Genetics BEST1 clinical trial?

In the Phase 1/2 OPGx-BEST1 trial, three out of four evaluable patients showed gains in retinal sensitivity in the low-dose group. Cohort 2 for the higher dose has completed enrollment with 11 patients.

When will Opus Genetics begin Phase 3 trial dosing for LCA5?

Opus Genetics plans to begin Phase 3 dosing for its OPGx-LCA5 gene therapy program in the fourth quarter of 2026. Adult participants in earlier testing maintained visual gains for 24 months.

How did Opus Genetics stock react to its clinical trial update?

Opus Genetics stock fell 2.07% to close at $4.015 despite reporting positive clinical data for its lead gene therapy candidates.